[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610888":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":53,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"non diabetic","EXPERIMENTAL","After inclusion, the subjects will have an OGTT performed in the department of non-diabetic subjects in Guadeloupe, from African or Indian origin who have risk factors of diabetes associated with normal FBG levels but HbA1c levels between 5.7 and 6.4%.",[13],"Diagnostic Test: After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A contr",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A contr","After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A control of the HbA1c levels will be also performed associated with a physical examination.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Fritz-Line VELAYOUDOM, Doctor","CHU de la Guadeloupe","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Valérie HAMONY-SOTER","CONTACT","+590 590 93 46 77","valerie.soter@chu-guadeloupe.fr",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":34},"Eunice NUBRET","eunice.nubret@chu-guadeloupe.fr",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":39,"countryCode":20,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Pointe-à-Pitre","Guadeloupe","97159",{"type":42,"coordinates":43},"Point",[44,45],-61.53459,16.23638,{"lat":45,"lon":44},[48,50,52],{"name":28,"role":29,"phone":49,"phoneExt":20,"email":31},"+590590934686",{"name":33,"role":29,"phone":51,"phoneExt":20,"email":34},"0590934686",{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100610888","screening-for-type-2-diabetes-by-oral-glucose-tolerance-test-in-the-population-groups-not-diagnosed-by-fasting-blood-glucose-in-guadeloupe-100610888",false,"NCT07233434","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe: a Pilot Study","DIADEG","o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg\u002FdL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \\> 25 kg\u002Fm2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia.\n\nAffiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam)\n\no Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and \u002F or psychological health, which, according to the investigator, may affect the compliance of the study participant",true,"ALL","18 Years","65 Years",{"count":68,"type":69},120,"ESTIMATED","INTERVENTIONAL",[72],"NA","In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.",[75],"Non-Diabetic",[77,78,79,80,81],"oral glucose tolerance","type 2 diabetes mellitus","Fasting blood glucose","HbA1c","screening","2025-11-14",{"date":84,"type":85},"2025-11-18","ACTUAL",{"date":87,"type":85},"2021-02-02",{"date":89,"type":69},"2028-08-02",{"name":5,"class":6},1]